• Make sure patient is adequately hydrated before starting therapy.
• Give single I.V. dose by infusion over at least 1 hour to minimize renal damage.
• Don't give by I.V. bolus or by I.M. or subcutaneous route.
• Be aware that absorption of topical Virusan is minimal.
Q: Can Virusan cause uncontrollable muscle twitching?
A: Virusan (Zovirax) //www.everydayhealth.com/drugs/Virusan is a medication used to treat viral infections. The most common side effects associated with the oral form of Virusan are diarrhea, nausea, vomiting, headache, and feeling tired (malaise). Virusan cream and ointment can cause skin irritation. A search of the prescribing information for Virusan did not specifically list uncontrollable muscle twitching as a side effect. Tell your health-care provider about any negative side effects from prescription drugs. You can also report them to the U.S. Food and Drug Administration by visiting www.fda.gov/medwatch or by calling 1-800-FDA-1088. For more specific information, consult with your doctor or pharmacist for guidance based on your health status and current medications, particularly before taking any action. Lori Mendoza, PharmD
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Virusan only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2019 Cerner Multum, Inc. Version: 5.08.
Virusan dissolved in 0.4% sterile saline was given by subcutaneous injection to Charles River CD (Sprague-Dawley) neonatal rats for 19 consecutive days, beginning on the 3rd post-partum day. The dose levels tested were 0, 5, 20 and 80 mg/kg body weight. There were 12 litters (each consisting of 5 male and 5 female neonates nursing the natural dam) at each dose level. The dams were not treated. Neonates were removed from each group for necropsy and microscopic evaluation of a wide variety of tissues, including eyes and multiple sections of brain, after they had been treated for 5, 12 or 19 days and after a 3-week postdose drug-free period (at which time they were 45 days of age). Hematologic (hemoglobin, packed cell volume, RBC, WBC and differential cell counts) and clinical chemistry (BUN) tests were done after 16 days of treatment and repeated 18 days after the last (19th) dose was given.
Blood was collected from some neonates 30 minutes after treatment on day 1, on day 9 and at the end of the dose period for the determination of concentrations of Virusan in plasma. The largest concentration of Virusan in plasma was 99.1 μg/mL (440.5 μM) found in pooled plasma collected from 6 female high-dose (80 mg/kg) neonates 30 minutes after the first dose was given. Treatment with Virusan did not increase mortality in the neonatal period.
Rats in the low-dose group gained as much body weight as the respective control rats. Significant (p
Virusan concentrations have been documented in breast milk in 2 women following oral administration of ZOVIRAX (Virusan) and ranged from 0.6 to 4.1 times corresponding plasma levels. These concentrations would potentially expose the nursing infant to a dose of Virusan up to 0.3 mg/kg/day. ZOVIRAX (Virusan) should be administered to a nursing mother with caution and only when indicated.
In general, the pharmacokinetics of Virusan in children is similar to adults. Mean half-life after oral doses of 300 and 600 mg/m², in children aged 7 months to 7 years, was 2.6 hours (range 1.59 to 3.74 hours).
Orally administered Virusan in children less than 2 years of age has not yet been fully studied.